Bone health and maintenance of bone integrity are important components of comprehensive cancer care in both early and late stages of disease. Risk factors for osteoporosis are increased in patients with cancer, including women with chemotherapy-induced ovarian failure, those treated with aromatase inhibitors for breast cancer, men receiving androgen-deprivation therapy for prostate cancer, and patients undergoing glucocorticoid therapy. The skeleton is a common site of metastatic cancer recurrence, and skeletal-related events are the cause of significant morbidity. The National Comprehensive Cancer Network (NCCN) convened a multidisciplinary task force on Bone Health in Cancer Care to discuss the progress made in identifying effective screening and therapeutic options for management of treatment-related bone loss; understanding the factors that result in bone metastases; managing skeletal metastases; and evolving strategies to reduce bone recurrences. This report summarizes presentations made at the meeting.

If the inline PDF is not rendering correctly, you can download the PDF file here.

References

  • 1

    JemalASiegelRWardE. Cancer statistics, 2008. CA Cancer J Clin2008;58:7196.

  • 2

    ColemanRE. Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res2006;12:6243s6249s.

  • 3

    JohnellOKanisJAOdenA. Predictive value of BMD for hip and other fractures. J Bone Miner Res2005;20:11851194.

  • 4

    KanisJABorgstromFDe LaetC. Assessment of fracture risk. Osteoporosis Int2005;16:581589.

  • 5

    MohlerJAmlingCLBahnsonRR. NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer version 2.2009.Available at: http://www.nccn.org. Last accessed 8 June 2009.

  • 6

    CarlsonRWAllredDCAndersonBO. NCCN Clinical Practice Guidelines in Oncology: Breast Cancer version I.2009.Available at: http://www.nccn.org. Last accessed 8 June 2009.

  • 7

    U.S. Preventive Services Task Force. Screening for osteoporosis in postmenopausal women: recommendations and rationale. Ann Intern Med2002;137:526528.

  • 8

    HillnerBEIngleJNChlebowskiRT. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol2003;21:40424057.

  • 9

    KanisJAMeltonLJIIIChristiansenC. The diagnosis of osteoporosis. J Bone Miner Res1994;9:11371141.

  • 10

    World Health Organization Collaborating Centre for Metabolic Bone Diseases. FRAX WHO fracture risk assessment tool. Available at: http://www.shef.ac.uk/FRAX/. Accessed May 31 2009.

  • 11

    GarneroPDelmasPD. Biochemical markers of bone turnover in osteoporosis. In: MarcusMFeldmanDKelseyJ. eds. Osteoporosis. Vol 2. Academic Press; New York;459477.

  • 12

    GarneroPSornay-RenduEClaustratBDelmasPD. Biochemical markers of bone turnover, endogenous hormones and the risk of fractures in postmenopausal women: the OFELY study. J Bone Miner Res2000;15:15261536.

  • 13

    RossPDKressBCParsonRE. Serum bone alkaline phosphatase and calcaneus bone density predict fractures: a prospective study. Osteoporos Int2000;11:7682.

  • 14

    Sornay-RenduEMunozFGarneroP. Identification of osteopenic women at high risk of fracture: the OFELY study. J Bone Miner Res2005;20:18131819.

  • 15

    ChristgauSBitsch-JensenOHanover BjarnasonN. Serum CrossLaps for monitoring the response in individuals undergoing antiresorptive therapy. Bone2000;26:505511.

  • 16

    ChristgauS. Circadian variation in serum CrossLaps concentration is reduced in fasting individuals. Clin Chem2000;46:431.

  • 17

    EastellRMallinakNWeissS. Biological variability of serum and urinary N-telopeptides of type I collagen in postmenopausal women. J Bone Miner Res2000;15:594598.

  • 18

    ClowesJAHannonRAYapTS. Effect of feeding on bone turnover markers and its impact on biological variability of measurements. Bone2002;30:886890.

  • 19

    CauleyJAPalermoLVogtM. Prevalent vertebral fractures in black women and white women. J Bone Miner Res2008;23:14581467.

  • 20

    BlackDMArdenNKPalermoL. Prevalent vertebral deformities predict hip fractures and new vertebral deformities but not wrist fractures. Study of Osteoporotic Fractures Research Group. J Bone Miner Res1999;14:821828.

  • 21

    MeltonLJIIIAtkinsonEJCooperC. Vertebral fractures predict subsequent fractures. Osteoporos Int1999;10:214221.

  • 22

    GenantHKLiJWuCYShepherdJA. Vertebral fractures in osteoporosis: a new method for clinical assessment. J Clin Densitom2000;3:281290.

  • 23

    Physicians guide to prevention and treatment of osteoporosis. National Osteoporosis Foundation guideline.Belle Mead, NJ:Excerpta Medica, Inc;1999.

  • 24

    FeskanichDWillettWColditzG. Walking and leisure-time activity and risk of hip fracture in postmenopausal women. JAMA2002;288:23002306.

  • 25

    Centers for Disease Control and Prevention. Fatalities and injuries from falls among older adults—United States, 1993-2003 and 2001-2005. MMWR Morb Mortal Wkly Rep2006;55:12211224.

  • 26

    TinettiMESpeechleyMGinterSF. Risk factors for falls among elderly persons living in the community. N Eng J Med1988;317:17011707.

  • 27

    TinettiMEWilliamsCS. The effect of falls and fall injuries on functioning in community-dwelling older persons. J Gerontol A Biol Sci Med Sci1998;53:M112M119.

  • 28

    National Osteoporosis Foundation. Patient info: fall prevention.Available at: http://www.nof.org/patientinfo/fall_prevention.htm. Accessed May 2009.

  • 29

    ParkerMJGillespieWJGillespieLD. Effectiveness of hip protectors for preventing hip fractures in elderly people: systematic review. BMJ2006;332:571574.

  • 30

    SawkaAMBoulosPBeattieK. Hip protectors decrease hip fracture risk in elderly nursing home residents: a Bayesian meta-analysis. J Clin Epidemiol2007;60:336344.

  • 31

    ChapuyMCArlotMEDuboeufF. Vitamin D3 and calcium to prevent hip fractures in the elderly women. N Engl J Med1992;327:16371642.

  • 32

    Dawson-HughesBHarrisSSKrallEADallalGE. Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older. N Engl J Med1997;337:670676.

  • 33

    National Institutes of Health: Office of Dietary Supplements. Dietary supplement fact sheet: calcium.Available at: http://ods.od.nih.gov/factsheets/calcium.asp. Accessed May 2009.

  • 34

    National Institutes of Health: Office of Dietary Supplements. Dietary supplement fact sheet: vitamin D.Available at: http://ods.od.nih.gov/factsheets/vitamind.asp. Accessed May 2009.

  • 35

    Office of the Surgeon General. Bone health and osteoporosis: a report of the surgeon general. Issued October 14 2004. Available at: http://www.surgeongeneral.gov/library/bonehealth/index.html. Accessed May 2009.

  • 36

    Standing Committee on the Scientific Evaluation of Dietary Reference Intakes Food and Nutrition Board Institute of Medicine. Dietary Reference Intakes for Calcium Phosphorus Magnesium Vitamin D and Fluoride.Washington, DC; National Academy Press; 1997.

  • 37

    CurhanGCWillettWCSpeizerFE. Comparison of dietary calcium with supplemental calcium and other nutrients as factors affecting the risk for kidney stones in women. Ann Intern Med1997;126:497504.

  • 38

    AdamsJSKantorovichVWuC. Resolution of vitamin D insufficiency in osteopenic patients results in rapid recovery of bone mineral density. J Clin Endocrinol Metab1999;84:27292730.

  • 39

    Bischoff-FerrariHADawson-HughesBWillettWC. Effect of vitamin D on falls: a meta-analysis. JAMA2004;291:19992006.

  • 40

    HolickMF. Vitamin D deficiency. N Engl J Med2007;357:266281.

  • 41

    CranneyCHorselyTO’DonnellS. Effectiveness and safety of vitamin D. Evidence Report/Technology Assessment No. 158 AHRQ Publication No. 07-E013.Rockville: Agency for Healthcare Research and Quality; 2007.

  • 42

    HoughtonLAViethR. The case against ergocalciferol (vitamin D2) as a vitamin supplement. Am J Clin Nutr2006;84:694697.

  • 43

    HolickMFBiancuzzoRMChenTC. Vitamin D2 is as effective as vitamin D3 in maintaining circulating concentrations of 25-hydroxyvitamin D. J Clin Endocrinol Metab2008;93:677681.

  • 44

    MacLeanCNewberrySMaglioneM. Systematic review: comparative effectiveness of treatments to prevent fractures in men and women with low bone density or osteoporosis. Ann Intern Med2008;148:197213.

  • 45

    FleischH. Bisphosphonates: mechanisms of action. Endocr Rev1998;19:80100.

  • 46

    SmithMREasthamJGleasonDM. Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J Urol2003;169:20082012.

  • 47

    SmithMRMcGovernFJZeitmanAL. Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. N Engl J Med2001;345:948955.

  • 48

    TauchmanovaLColaoALombardiG. Bone loss and its management in long-term survivors from allogeneic stem cell transplantation. J Clin Endocrinol Metab2007;92:45364545.

  • 49

    RossouwJEAndersonGLPrenticeRL. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA2002;288:321333.

  • 50

    KhanMNKhanAA. Cancer treatment-related bone loss: a review and synthesis of the literature. Curr Oncol2008;15:S3040.

  • 51

    ChangJTGreenLBeitzJ. Renal failure with the use of zoledronic acid. N Engl J Med2003;349:16761679.

  • 52

    Van PoznakCEstiloC. Osteonecrosis of the jaw in cancer patients receiving IV bisphosphonates. Oncology (Williston Park)2006;20:10531062.

  • 53

    KhoslaSBurrDCauleyJ. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res2007;22:14791491.

  • 54

    WooSBHellsteinJWKalmarJR. Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med2006;144:753761.

  • 55

    BrufskyABundredNColemanR. Integrated analysis of zoledronic acid for prevention of aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole. Oncologist2008;13:503514.

  • 56

    GnantMFMlineritschBLuschin-EbengreuthG. Zoledronic acid prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: a report from the Austrian Breast and Colorectal Cancer Study Group. J Clin Oncol2007;25:820828.

  • 57

    WeitzmanRSauterNEriksenEF. Critical review: updated recommendations for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in cancer patients—May 2006. Crit Rev Oncol Hematol2007;62:148152.

  • 58

    LylesKWColon-EmericCSMagazinerJS. Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med2007;357:17991809.

  • 59

    U.S. Food and Drug Administration. Update of safety review follow-up to the October 1 2007 early communication about the ongoing safety review of biophosphonates. Available at: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm136201.htm. Accessed May 2009.

  • 60

    GohSKYangKYKohJS. Subtrochanteric insufficiency fractures in patients on alendronate therapy: a caution. J Bone Joint Surg Br2007;89:349353.

  • 61

    KwekEBGohSKKohJS. An emerging pattern of subtrochanteric stress fractures: a long-term complication of alendronate therapy?Injury2008;39:224231.

  • 62

    OlsonKVan PoznakC. Significance and impact of bisphosphonate-induced acute phase responses. J Oncol Pharm Pract2007;13:223229.

  • 63

    HolmbergLAndersonH. HABITS (hormonal replacement therapy after breast cancer—is it safe?), a randomised comparison: trial stopped. Lancet2004;363:453455.

  • 64

    Christin-MaitreS. The role of hormone replacement therapy in the management of premature ovarian failure. Nat Clin Pract Endocrinol Metab2008;4:6061.

  • 65

    EttingerBBlackDMMitlakBH. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA1999;282:637645.

  • 66

    Barrett-ConnorEMoscaLCollinsP. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med2006;355:125137.

  • 67

    MartinoSCauleyJABarrett-ConnorE. Continuing outcomes relevant to EVISTA: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. J Natl Cancer Inst2004;96:17511761.

  • 68

    VogelVGCostantinoJPWickerhamDL. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA2006;295:27272741.

  • 69

    CauleyJANortonLLippmanME. Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple Outcomes of Raloxifene Evaluation. Breast Cancer Res Treat2001;65:125134.

  • 70

    O’ReganRMGajdosCDardesRC. Effects of raloxifene after tamoxifen on breast and endometrial tumor growth in athymic mice. J Natl Cancer Inst2002;94:274283.

  • 71

    StewartHJForrestAPEveringtonD. Randomised comparison of 5 years of adjuvant tamoxifen with continuous therapy for operable breast cancer. The Scottish Cancer Trials Breast Group. Br J Cancer1996;74:297299.

  • 72

    Eng-WongJReynoldsJCVenzonD. Effect of raloxifene on bone mineral density in premenopausal women at increased risk of breast cancer. J Clin Endocrinol Metab2006;91:39413946.

  • 73

    BaumMBuzdarACuzickJ. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses. Cancer2003;98:18021810.

  • 74

    GossPBondarenkoINManikhasGN. Phase III, double-blind, controlled trial of atamestane plus toremifene compared with letrozole in postmenopausal women with advanced receptor-positive breast cancer. J Clin Oncol2007;25:49614966.

  • 75

    Refer http://www.accessdata.fda.gov/Scripts/cder/DrugsatFDA/index.cfm?fuseaction=Search.DrugDetailsfor latest package insert.

  • 76

    BraunSVoglFDNaumeB. A pooled analysis of bone marrow micrometastasis in breast cancer. N Engl J Med2005;353:793802.

  • 77

    FarookiAFornierMGirotraM. Anabolic therapies for osteoporosis. N Engl J Med2007;357:24102411.

  • 78

    CummingsSRMcClungMRChristiansenC. A phase III study of the effects of denosumab on vertebral, nonvertebral, and hip fracture in women with osteoporosis: results from the FREEDOM trial [abstract]. Presented at the American Society of Bone and Mineral Research 30th Annual Meeting; September 12–16, 2008; Montreal, Quebec, Canada. Abstract 1286.

  • 79

    BrownJPDealCde GregorinLH. Effect of densoumab vs alendronate on bone turnover markers and bone mineral density changes at 12 months based on baseline bone turnover level [abstract]. Presented at the American Society of Bone and Mineral Research 30th Annual Meeting; September 12–16, 2008; Montreal, Quebec, Canada. Abstract 1285.

  • 80

    KendlerDLBenhamouCLBrownJP. Effects of denosumab vs. alendronate on bone mineral density (BMD), bone turnover markers (BTM), and safety in women previously treated with alendronate [abstract]. Presented at the American Society of Bone and Mineral Research 30th Annual Meeting; September 12–16, 2008; Montreal, Quebec, Canada. Abstract 138.

  • 81

    ChesnutCHIIIBellNHClarkGS. Hormone replacement therapy in postmenopausal women: urinary N-telopeptide of type I collagen monitors therapeutic effect and predicts response of bone mineral density. Am J Med1997;102:2937.

  • 82

    RavnPClemmesenBChristiansenC. Biochemical markers can predict the response in bone mass during alendronate treatment in early postmenopausal women. Alendronate Osteoporosis Prevention Study Group. Bone1999;24:237244.

  • 83

    ToninoRPMeunierPJEmkeyR. Skeletal benefits of alendronate: 7-year treatment of postmenopausal osteoporotic women. Phase III Osteoporosis Treatment Study Group. J Clin Endocrinol Metab2000;85:31093115.

  • 84

    BlackDMSchwartzAVEnsrudKE. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA2006;296:29272938.

  • 85

    PfeilschifterJDielIJ. Osteoporosis due to cancer treatment: pathogenesis and management. J Clin Oncol2000;18:15701593.

  • 86

    FornierMNModiSPanageasKS. Incidence of chemotherapy-induced, long-term amenorrhea in patients with breast carcinoma age 40 years and younger after adjuvant anthracycline and taxane. Cancer2005;104:15751579.

  • 87

    BursteinHJWinerEP. Primary care for survivors of breast cancer. N Engl J Med2000;343:10861094.

  • 88

    GoodwinPJEnnisMPritchardKI. Risk of menopause during the first year after breast cancer diagnosis. J Clin Oncol1999;17:23652370.

  • 89

    PetrekJANaughtonMJCaseLD. Incidence, time course, and determinants of menstrual bleeding after breast cancer treatment: a prospective study. J Clin Oncol2006;24:10451051.

  • 90

    ShapiroCLManolaJLeboffM. Ovarian failure after adjuvant chemotherapy is associated with rapid bone loss in women with early-stage breast cancer. J Clin Oncol2001;19:33063311.

  • 91

    HeadleyJATheriaultRLLeBlancAD. Pilot study of bone mineral density in breast cancer patients treated with adjuvant chemotherapy. Cancer Invest1998;16:611.

  • 92

    PowlesTJMcCloskeyEPatersonAH. Oral clodronate and reduction in loss of bone mineral density in women with operable primary breast cancer. J Natl Cancer Inst1998;90:704708.

  • 93

    SaartoTBlomqvistCValimakiM. Chemical castration induced by adjuvant cyclophosphamide, methotrexate, and fluorouracil chemotherapy causes rapid bone loss that is reduced by clodronate: a randomized study in premenopausal breast cancer patients. J Clin Oncol1997;15:13411347.

  • 94

    HershmanDLMcMahonDJCrewKD. Zoledronic acid prevents bone loss in premenopausal women undergoing adjuvant chemotherapy for early-stage breast cancer. J Clin Oncol2008;26:47394745.

  • 95

    DelmasPDBalenaRConfravreuxE. Bisphosphonate risedronate prevents bone loss in women with artificial menopause due to chemotherapy of breast cancer: a double-blind, placebo-controlled study. J Clin Oncol1997;15:955962.

  • 96

    WarmingLHassagerCChristiansenC. Changes in bone mineral density with age in men and women: a longitudinal study. Osteoporos Int2002;13:105112.

  • 97

    EastellRHannonRACuzickJ. Effect of an aromatase inhibitor on bmd and bone turnover markers: 2-year results of the Anastrozole, Tamoxifen, Alone or in Combination (ATAC) trial (18233230). J Bone Miner Res2006;21:12151223.

  • 98

    FogelmanIBlakeGMBlameyR. Bone mineral density in premenopausal women treated for node-positive early breast cancer with 2 years of goserelin or 6 months of cyclophosphamide, methotrexate and 5-fluorouracil (CMF). Osteoporos Int2003;14:10011006.

  • 99

    HershmanDLMcMahonDJCrewKD. Zoledronic acid prevents bone loss in premenopausal women undergoing adjuvant chemotherapy for early-stage breast cancer. J Clin Oncol2008;26:47394745.

  • 100

    RippsBAVanGilderKMinhasB. Alendronate for the prevention of bone mineral loss during gonadotropin-releasing hormone agonist therapy. J Reprod Med2003;48:761766.

  • 101

    GnantMMlineritschBSchippingerW. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med2009;360:679691.

  • 102

    GossPWuM. Application of aromatase inhibitors in endocrine responsive breast cancers. Breast2007;16(Suppl 2):S114119.

  • 103

    GeislerJLonningPE. Endocrine effects of aromatase inhibitors and inactivators in vivo: review of data and method limitations. J Steroid Biochem Mol Biol2005;95:7581.

  • 104

    SimpsonERDowsettM. Aromatase and its inhibitors: significance for breast cancer therapy. Recent Prog Horm Res2002;57:317338.

  • 105

    KhanMNKhanAA. Cancer treatment-related bone loss: a review and synthesis of the literature. Curr Oncol2008;15:S3040.

  • 106

    ChowdhurySPickeringLMEllisPA. Adjuvant aromatase inhibitors and bone health. J Br Menopause Soc2006;12:97103.

  • 107

    BodyJJBergmannPBoonenS. Management of cancer treatment-induced bone loss in early breast and prostate cancer—a consensus paper of the Belgian Bone Club. Osteoporos Int2007;18:14391450.

  • 108

    PerezEA. Safety of aromatase inhibitors in the adjuvant setting. Breast Cancer Res Treat2007;105(Suppl 1):7589.

  • 109

    ForbesJFCuzickJBuzdarA. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol2008;9:4553.

  • 110

    ThurlimannBKeshaviahACoatesAS. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med2005;353:27472757.

  • 111

    CoombesRCHallEGibsonLJ. Intergroup Exemestane Study: a randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med2004;350:10811092.

  • 112

    ColemanREBanksLMGirgisSI. Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study. Lancet Oncol2007;8:119127.

  • 113

    National Cancer Institute. Phase III randomized adjuvant study of exemestane versus anastrozole in postmenopausal women receptor-positive primary breast cancer. Available at: http://www.cancer.gov/clinicaltrials/CAN-NCIC-MA27. Last accessed 8 June 2009.

  • 114

    GossPEIngleJNMartinoS. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med2003;349:17931802.

  • 115

    ColemanRE. Effect of anastrozole on bone mineral density: 5-year results from the ‘Arimidex’, Tamoxifen, Alone or in Combination (ATAC) trial [abstract]. J Clin Oncol2006;24(Suppl 1):5s. Abstract 511.

  • 116

    Van PoznakCHannonRAClackG. The SABRE study: effects of risedronate on bone mineral density and bone metabolism in postmenopausal women using anastrozole as adjuvant therapy for hormone receptor-positive early stage breast cancer—first results [abstract]. Breast Cancer Res Treat2006;100(Suppl 1):Abstract 4061.

  • 117

    Van PoznakCHannonRClackG. Managing cancer treatment-induced bone loss: 24-month results from the Study of Anastrozole with the Bisphosphonate RisedronatE (SABRE). San Antonio Breast Cancer symposiumAbstract 1137.

  • 118

    LesterJEGutcherSAEllisS. Use of monthly oral ibandronate to prevent anastrozole-induced bone loss during adjuvant treatment for breast cancer: two-year results from the ARIBON study [abstract]. J Clin Oncol2008;26(Suppl 1):Abstract 554.

  • 119

    BundredNJCampbellIDDavidsonN. Effective inhibition of aromatase inhibitor-associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving letrozole: ZO-FAST study results. Cancer2008;112:10011010.

  • 120

    SchenkNLlombartA. The E-ZO-FAST trial: zoledronic acid (ZA) effectively inhibits aromatase inhibitor associated bone loss (AIBL) in postmenopausal women (PMW) with early breast cancer (EBC) receiving adjuvant letrozole [abstract]. Presented at the 14th European Cancer Conference; September 23–27, 2007; Barcelona, Spain. Abstract 2008.

  • 121

    EllisGKBoneHGChlebowskiR. Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer. J Clin Oncol2008;26:48754882.

  • 122

    GuiseTAOefeleinMGEasthamJA. Estrogenic side effects of androgen deprivation therapy. Rev Urol2007;9:163180.

  • 123

    BasariaSLiebJIITangAM. Long-term effects of androgen deprivation therapy in prostate cancer patients. Clin Endocrinol (Oxf)2002;56:779786.

  • 124

    KhoslaSMeltonLJIIIAtkinsonEJO’FallonWM. Relationship of serum sex steroid levels to longitudinal changes in bone density in young versus elderly men. J Clin Endocrinol Metab2001;86:35553561.

  • 125

    MellstromDVandenputLMallminH. Older men with low serum estradiol and high serum SHBG have an increased risk of fractures. J Bone Miner Res2008;23:15521560.

  • 126

    SmithMRLeeWCBrandmanJ. Gonadotropin-releasing hormone agonists and fracture risk: a claims-based cohort study of men with nonmetastatic prostate cancer. J Clin Oncol2005;23:78977903.

  • 127

    ShahinianVBKuoYFFreemanJLGoodwinJS. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med2005;352:154164.

  • 128

    MittanDLeeSMillerE. Bone loss following hypogonadism in men with prostate cancer treated with GnRH analogs. J Clin Endocrinol Metab2002;87:36563661.

  • 129

    MaillefertJFSibiliaJMichelF. Bone mineral density in men treated with synthetic gonadotropin-releasing hormone agonists for prostatic carcinoma. J Urol1999;161:12191222.

  • 130

    DiamondTCampbellJBryantCLynchW. The effect of combined androgen blockade on bone turnover and bone mineral densities in men treated for prostate carcinoma: longitudinal evaluation and response to intermittent cyclic etidronate therapy. Cancer1998;83:15611566.

  • 131

    DaniellHWDunnSRFergusonDW. Progressive osteoporosis during androgen deprivation therapy for prostate cancer. J Urol2000;163:181186.

  • 132

    BerrutiADogliottiLTerroneC. Changes in bone mineral density, lean body mass and fat content as measured by dual energy x-ray absorptiometry in patients with prostate cancer without apparent bone metastases given androgen deprivation therapy. J Urol2002;167:23612367; discussion 2367.

  • 133

    SmithMRMcGovernFJZietmanAL. Pamidronate to prevent bone loss in men receiving gonadotropin releasing hormone agonist therapy for prostate cancer. N Engl J Med2001;345:948955.

  • 134

    SmithMREasthamJGleasonD. Randomized controlled trial of zoledronic acid to prevent bone loss in men undergoing androgen deprivation therapy for nonmetastatic prostate cancer. J Urol2003;169:20082012.

  • 135

    MichaelsonMDKaufmanDSLeeH. Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer. J Clin Oncol2007;25:10381042.

  • 136

    GreenspanSLNelsonJBTrumpDLResnickNM. Effect of once-weekly oral alendronate on bone loss in men receiving androgen deprivation therapy for prostate cancer: a randomized trial. Ann Intern Med2007;146:416424.

  • 137

    SmithMRFallonMALeeHFinkelsteinJS. Raloxifene to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer: a randomized controlled trial. J Clin Endocrinol Metab2004;89:38413846.

  • 138

    SmithMRMalkowiczSBChuF. Toremifene increases bone mineral density in men receiving androgen deprivation therapy for prostate cancer: interim analysis of a multicenter phase III clinical study. J Urol2008;179:152155.

  • 139

    SmithMRMalkowiczSBChuF. Toremifene improves lipid profiles in men receiving androgen-deprivation therapy for prostate cancer: interim analysis of a multicenter phase III study. J Clin Oncol2008;26:18241829.

  • 140

    SenaratneSGMansiJLColstonKW. The bisphosphonate zoledronic acid impairs Ras membrane [correction of impairs membrane] localisation and induces cytochrome c release in breast cancer cells. Br J Cancer2002;86:14791486.

  • 141

    van der PluijmGVloedgravenHvan BeekE. Bisphosphonates inhibit the adhesion of breast cancer cells to bone matrices in vitro. J Clin Invest1996;98:698705.

  • 142

    BoissierSFerrerasMPeyruchaudO. Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases. Cancer Res2000;60:29492954.

  • 143

    TeronenOKonttinenYTSaloT. [Bisphosphonates inhibit matrix metalloproteinases—a new possible mechanism of action]. Duodecim1999;115:1315[in Finnish].

  • 144

    BoissierSMagnettoSFrappartL. Bisphosphonates inhibit prostate and breast carcinoma cell adhesion to unmineralized and mineralized bone extracellular matrices. Cancer Res1997;57:38903894.

  • 145

    SasakiABoyceBFStoryB. Bisphosphonate risedronate reduces metastatic human breast cancer burden in bone in nude mice. Cancer Res1995;55:35513557.

  • 146

    PowlesTPatersonAMcCloskeyE. Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer [ISRCTN83688026]. Breast Cancer Res2006;8:R13.

  • 147

    DielIJSolomayerEFCostaSD. Reduction in new metastases in breast cancer with adjuvant clodronate treatment. New Engl J Med1998;339:357363.

  • 148

    DielIJJaschkeASolomayerEF. Adjuvant oral clodronate improves the overall survival of primary breast cancer patients with micrometastases to the bone marrow: a long-term follow-up. Ann Oncol2008;19:20072011.

  • 149

    SaartoTBlomqvistCVirkkunenPElomaaI. Adjuvant clodronate treatment does not reduce the frequency of skeletal metastases in node-positive breast cancer patients: 5-year results of a randomized controlled trial. J Clin Oncol2001;19:1017.

  • 150

    HaTCLiH. Meta-analysis of clodronate and breast cancer survival. Br J Cancer2007;96:17961801.

  • 151

    SmithMRKabbinavarFSaadF. Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer. J Clin Oncol2005;23:29182925.

  • 152

    MasonMDSydesMRGlaholmJ. Oral sodium clodronate for nonmetastatic prostate cancer--results of a randomized double-blind placebo-controlled trial: Medical Research Council PR04 (ISRCTN61384873). J Natl Cancer Inst2007;99:765776.

  • 153

    RoudierMPVesselleHTrueLD. Bone histology at autopsy and matched bone scintigraphy findings in patients with hormone refractory prostate cancer: the effect of bisphosphonate therapy on bone scintigraphy results. Clin Exp Metastasis2003;20:171180.

  • 154

    GuiseTAMohammadKSClinesG. Basic mechanisms responsible for osteolytic and osteoblastic bone metastases. Clin Cancer Res2006;12:6213s6216s.

  • 155

    RoodmanGD. Mechanisms of bone metastasis. N Engl J Med2004;350:16551664.

  • 156

    WithamTFKhavkinYAGalliaGL. Surgery insight: current management of epidural spinal cord compression from metastatic spine disease. Nat Clin Pract Neurol2006;2:8794; quiz 116.

  • 157

    ColemanRE. Skeletal complications of malignancy. Cancer1997;80:15881594.

  • 158

    TheriaultRLLiptonAHortobagyiGN. Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. Protocol 18 Aredia Breast Cancer Study Group. J Clin Oncol1999;17:846854.

  • 159

    HortobagyiGNTheriaultRLPorterL. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group. N Engl J Med1996;335:17851791.

  • 160

    RosenLSGordonDKaminskiM. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer J2001;7:377387.

  • 161

    KohnoNAogiKMinamiH. Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial. J Clin Oncol2005;23:33143321.

  • 162

    BodyJJDielIJLichinitzerM. Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomised, placebo-controlled phase III studies. Br J Cancer2004;90:11331137.

  • 163

    Tubiana-HulinMBeuzebocPMauriacL. [Double-blinded controlled study comparing clodronate versus placebo in patients with breast cancer bone metastases]. Bull Cancer2001;88:701707[in French].

  • 164

    DielIJBodyJJLichinitserMR. Improved quality of life after long-term treatment with the bisphosphonate ibandronate in patients with metastatic bone disease due to breast cancer. Eur J Cancer2004;40:17041712.

  • 165

    BodyJJDielIJBellR. Oral ibandronate improves bone pain and preserves quality of life in patients with skeletal metastases due to breast cancer. Pain2004;111:306312.

  • 166

    LiptonATheriaultRLHortobagyiGN. Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials. Cancer2000;88:10821090.

  • 167

    SaadFGleasonDMMurrayR. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst2004;96:879882.

  • 168

    KyleRAYeeGCSomerfieldMR. American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma. J Clin Oncol2007;25:24642472.

  • 169

    AaproMAbrahamssonPABodyJJ. Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel. Ann Oncol2008;19:420432.

  • 170

    MajorPLortholaryAHonJ. Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials. J Clin Oncol2001;19:558567.

  • 171

    RosenLSGordonDKaminskiM. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. Cancer2003;98:17351744.

  • 172

    KohnoNAogiKMinamiH. Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial. J Clin Oncol2005;23:33143321.

  • 173

    DearnaleyDPSydesMRMasonMD. A double-blind, placebo-controlled, randomized trial of sodium clodronate for metastatic prostate cancer (MRC PR05 trial). J Natl Cancer Inst2003;95:13001311.

  • 174

    ErnstDSTannockIFWinquistEW. Randomized, double-blind, controlled trial of mitoxantrone/prednisone and clodronate versus mitoxantrone/prednisone and placebo in patients with hormone-refractory prostate cancer and pain. J Clin Oncol2003;21:33353342.

  • 175

    SmallEJSmithMRSeamanJJ. Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer. J Clin Oncol2003;21:42774284.

  • 176

    SaadFGleasonDMMurrayR. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst2002;94:14581468.

  • 177

    ClinicalTrials.gov. Study to evaluate zoledronic acid on quality of life and skeletal-related events as adjuvant treatment in patients with hormone-naïve prostate cancer and bone metastasis who have undergone orchiectomy. Available at: http://www.clinicaltrial.gov/ct2/show/NCT00237146?term=hormone+naive+prostate+cancer&rank=4. Accessed May 2009.

  • 178

    ClinicalTrials.gov. Double-blind study of denosumab compared with zoledronic acid in the treatment of bone metastases in men with hormone-refractory prostate cancer. Available at: http://www.clinicaltrial.gov/ct2/show/NCT00321620?term=denosumab+and+prostate+cancer&rank=2. Accessed May 2009.

  • 179

    FizaziKLiptonAMarietteX. Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates. J Clin Oncol2009;27:15641571.

  • 180

    LiptonAStegerGGFigueroaJ. Randomized active-controlled phase II study of denosumab efficacy and safety in patients with breast cancer-related bone metastases. J Clin Oncol2007;25:44314437.

  • 181

    ClinicalTrials.gov. Dasatinib in treating patients with stage IV breast cancer that has spread to the bone. Available at: http://clinicaltrials.gov/ct2/show/NCT00410813. Accessed May 2009.

  • 182

    ClinicalTrials.gov. Dasatinib in combination with zoledronic acid for the treatment of breast cancer with bone metastasis. Available at: http://clinicaltrials.gov/ct2/show/NCT00566618?show_desc=Y. Accessed May 2009.

  • 183

    ClinicalTrials.gov. Trial of dasatinib (Sprycel®) in subjects with hormone-refractory prostate cancer. Available at: http://clinicaltrials.gov/ct2/show/NCT00570700. Accessed May 2009.

  • 184

    Le GallCBonnelyeEClezardinP. Cathepsin K inhibitors as treatment of bone metastasis. Curr Opin Support Palliat Care2008;2:218222.

  • 185

    Le GallCBellahceneABonnelyeE. A cathepsin K inhibitor reduces breast cancer induced osteolysis and skeletal tumor burden. Cancer Res2007;67:98949902.

  • 186

    ClinicalTrials.gov. Archive: view of NCT00692458 on 2008_12_07. Available at: http://clinicaltrials.gov/archive/NCT00692458/2008_12_07. AccessedMay 2009.

  • 187

    MuindiJCoombesRCGoldingS. The role of computed tomography in the detection of bone metastases in breast cancer patients. Br J Radiol1983;56:233236.

  • 188

    DurningPBestJJSellwoodRA. Recognition of metastatic bone disease in cancer of the breast by computed tomography. Clin Oncol1983;9:343346.

  • 189

    HannaSLFletcherBDFaircloughDL. Magnetic resonance imaging of disseminated bone marrow disease in patients treated for malignancy. Skeletal Radiol1991;20:7984.

  • 190

    KrishnamurthyGTTubisMHissJBlahdWH. Distribution pattern of metastatic bone disease. A need for total body skeletal image. JAMA1977;237:25042506.

  • 191

    ZelinkaTTimmersHJKozupaA. Role of positron emission tomography and bone scintigraphy in the evaluation of bone involvement in metastatic pheochromocytoma and paraganglioma: specific implications for succinate dehydrogenase enzyme subunit B gene mutations. Endocr Relat Cancer2008;15:311323.

  • 192

    Daldrup-LinkHEFranziusCLinkTM. Whole-body MR imaging for detection of bone metastases in children and young adults: comparison with skeletal scintigraphy and FDG PET. Am J Roentgenol2001;177:229236.

  • 193

    OhtaMTokudaYSuzukiY. Whole body PET for the evaluation of bony metastases in patients with breast cancer: comparison with 99Tcm-MDP bone scintigraphy. Nucl Med Commun2001;22:875879.

  • 194

    KaoCHHsiehJFTsaiSC. Comparison and discrepancy of 18F-2-deoxyglucose positron emission tomography and Tc-99m MDP bone scan to detect bone metastases. Anticancer Res2000;20:21892192.

  • 195

    HamaokaTMadewellJEPodoloffDA. Bone imaging in metastatic breast cancer. J Clin Oncol2004;22:29422953.

  • 196

    ChowEHarrisKFanG. Palliative radiotherapy trials for bone metastases: a systematic review. J Clin Oncol2007;25:14231436.

  • 197

    WuJSWongRJohnstonM. Meta-analysis of dose-fractionation radiotherapy trials for the palliation of painful bone metastases. Int J Radiat Oncol Biol Phys2003;55:594605.

  • 198

    HartsellWFScottCBBrunerDW. Randomized trial of short- versus long-course radiotherapy for palliation of painful bone metastases. J Natl Cancer Inst2005;97:798804.

  • 199

    van den HoutWBvan der LindenYMSteenlandE. Single-versus multiple-fraction radiotherapy in patients with painful bone metastases: cost-utility analysis based on a randomized trial. J Natl Cancer Inst2003;95:222229.

  • 200

    BradleyNMHustedJSeyMS. Review of patterns of practice and patients’ preferences in the treatment of bone metastases with palliative radiotherapy. Support Care Cancer2007;15:373385.

  • 201

    GersztenPCBurtonSAWelchWC. Single-fraction radiosurgery for the treatment of spinal breast metastases. Cancer2005;104:22442254.

  • 202

    QuiltyPMKirkDBolgerJJ. A comparison of the palliative effects of strontium-89 and external beam radiotherapy in metastatic prostate cancer. Radiother Oncol1994;31:3340.

  • 203

    PorterATMcEwanAJBPoweJE. Results of a randomized phase III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer. Int J Radiat Oncol Biol Phys1993;25:805813.

  • 204

    RobinsonRG. Strontium-89-precursor targeted therapy for pain relief of blastic metastatic disease. Cancer1993;72:34333435.

  • 205

    SartorOReidRHHoskinPJ. Samarium-153-Lexidronam complex for treatment of painful bone metastases in hormone-refractory prostate cancer. Urology2004;63:940945.

  • 206

    MaxonHRSchroderLEHertzbergVS. Rhenium-186(Sn)-HEDP for treatment of painful osseous metastases: results of a double blind crossover comparison with placebo. J Nucl Med1991;32:18771881.

  • 207

    PalmedoHManka-WaluchAAlbersP. Repeated bone-targeted therapy for hormone-refractory prostate carcinoma: randomized phase II trial with the new, high-energy radiopharmaceutical rhenium-188 hydroxyethylidenediphosphonate. J Clin Oncol2003;21:28692875.

  • 208

    TuSMillikanREMengistuB. Bone targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomised phase II trial. Lancet2001;357:336341.

  • 209

    WardWGHolsenbeckSDoreyFJ. Metastatic disease of the femur: surgical treatment. Clin Orthop Relat Res2003:S230244.

  • 210

    RedmondBJBiermannJSBlasierRB. Interlocking intramedullary nailing of pathological fractures of the shaft of the humerus. J Bone Joint Surg Am1996;78A:891896.

  • 211

    FranckWMOlivieriMJannaschOHennigFF. An expandable nailing system for the management of pathological humerus fractures. Arch Orthop Trauma Surg2002;122:400405.

  • 212

    SamsaniSRPanikkarVVenuKM. Breast cancer bone metastasis in femur: surgical considerations and reconstruction with Long Gamma Nail. Eur J Surg Oncol2004;30:993997.

  • 213

    MoholkarKMohanRGrigorisP. The Long Gamma Nail for stabilisation of existing and impending pathological fractures of the femur: an analysis of 48 cases. Acta Orthop Belg2004;70:429434.

  • 214

    MarcoRAShethDSBolandPJ. Functional and oncological outcome of acetabular reconstruction for the treatment of metastatic disease. J Bone Joint Surg Am2000;82:642651.

  • 215

    BeneveniaJCyranFPBiermannJS. Treatment of advanced metastatic lesions of the acetabulum using the saddle prosthesis. Clin Orthop Relat Res2004:2331.

  • 216

    GoetzMPCallstromMRCharboneauJW. Percutaneous image-guided radiofrequency ablation of painful metastases involving bone: a multicenter study. J Clin Oncol2004;22:300306.

  • 217

    FourneyDRSchomerDFNaderR. Percutaneous vertebroplasty and kyphoplasty for painful vertebral body fractures in cancer patients. J Neurosurg2003;98:2130.

  • 218

    LaneJMHongRKoobJ. Kyphoplasty enhances function and structural alignment in multiple myeloma. Clin Orthop Relat Res2004;426:4953.

  • 219

    KelekisALovbladKOMehdizadeA. Pelvic osteoplasty in osteolytic metastases: technical approach under fluoroscopic guidance and early clinical results. J Vasc Interv Radiol2005;16:8188.

  • 220

    CallstromMRCharboneauJWGoetzMP. Image-guided ablation of painful metastatic bone tumors: a new and effective approach to a difficult problem. Skeletal Radiol2006;35:115.

  • 221

    KalantaridouSNDavisSRNelsonLM. Premature ovarian failure. Endocrinol Metab Clin North Am1998;27:9891006.

  • 222

    BerensonJRLichtensteinAPorterL. Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group. J Clin Oncol1998;16:593602.

  • 223

    RosenLSGordonDTchekmedyianNS. Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, phase III, double-blind, placebo-controlled trial. Cancer2004;100:26132621.

Article Information

PubMed

Google Scholar

Related Articles

Metrics

All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 28 28 17
PDF Downloads 19 19 14
EPUB Downloads 0 0 0